Regenerative medicine company, Regeneus (ASX: RGS) announced today that it has entered into an agreement with a leading US vet health care services group to conduct a marketing trial in the United States of the company’s novel autologous canine therapeutic cancer vaccine, Kvax.
“We are delighted that we have now agreed the design and implementation of our initial US marketing trial for Kvax. The trial will provide important efficacy data in a single defined tumour type and increase awareness of the new cancer treatment with vets and dog owners in the United States,” says Dr Duncan Thomson – Head of the Veterinary Business Unit for Regeneus.
This follows on from the company’s announcement in November 2013 that the US Center for Veterinary Biologics gave the green light for the US commercialisation of Kvax and in April 2014, that Regeneus entered into an agreement with Hennessy Research to manufacture the vaccine for the US market.
Kvax uses the removal of a small amount of tumour or biopsy from the patient as source material to produce a truly personalised cancer treatment. The therapeutic vaccine stimulates the dog’s immune system to see the cancer cells as foreign and helps prevent further growth of the tumour and the development of new tumours.
The cancer vaccine was developed at the Bill Walsh Translational Cancer Research Laboratory, which is part of the Kolling Institute of Medical Research at the Royal North Shore Hospital in Sydney. Positive safety and early efficacy data was published in February 2014 by Cancer Immunology Research, the peer-reviewed journal published by the American Association for Cancer Research.
The Morris Animal Foundation, a leading US non-profit animal research foundation, has found that cancer accounts for over half the deaths of dogs over 10 years of age, which is roughly the same rate as humans. It is estimated than more than 4 million dogs develop cancer in the US each year which equates to a newly diagnosed case every 8 seconds. It remains by far the largest health concern of dog owners.